BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

295 related articles for article (PubMed ID: 17356271)

  • 1. Retrospective evaluation of sequential outpatient chemotherapy for advanced gastric cancer.
    Satoh S; Kawashima K; Matsumoto S; Hasegawa S; Okabe H; Nomura A; Yoshibayashi H; Watanabe G; Nagayama S; Fukushima M; Sakai Y
    Chemotherapy; 2007; 53(3):226-32. PubMed ID: 17356271
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Randomised phase III trial of second-line irinotecan plus cisplatin versus irinotecan alone in patients with advanced gastric cancer refractory to S-1 monotherapy: TRICS trial.
    Nishikawa K; Fujitani K; Inagaki H; Akamaru Y; Tokunaga S; Takagi M; Tamura S; Sugimoto N; Shigematsu T; Yoshikawa T; Ishiguro T; Nakamura M; Morita S; Miyashita Y; Tsuburaya A; Sakamoto J; Tsujinaka T
    Eur J Cancer; 2015 May; 51(7):808-16. PubMed ID: 25797356
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase II study of biweekly S-1 and paclitaxel (SPA) as first-line chemotherapy in patients with metastatic or advanced gastric cancer.
    Jiang H; Qian J; Zhao P; Zhang X; Zheng Y; Mao C; Zheng Y; Chen L; Wang Y; Mou H; Fang W; Teng L; Xu N
    Cancer Chemother Pharmacol; 2015 Jul; 76(1):197-203. PubMed ID: 26013324
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [S-1 for gastric cancer-S-1 monotherapy and its progress].
    Shitara K; Sakata Y; Kudou T; Munakata M
    Gan To Kagaku Ryoho; 2006 Jun; 33 Suppl 1():43-51. PubMed ID: 16897971
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sequential paclitaxel followed by tegafur and uracil (UFT) or S-1 versus UFT or S-1 monotherapy as adjuvant chemotherapy for T4a/b gastric cancer (SAMIT): a phase 3 factorial randomised controlled trial.
    Tsuburaya A; Yoshida K; Kobayashi M; Yoshino S; Takahashi M; Takiguchi N; Tanabe K; Takahashi N; Imamura H; Tatsumoto N; Hara A; Nishikawa K; Fukushima R; Nozaki I; Kojima H; Miyashita Y; Oba K; Buyse M; Morita S; Sakamoto J
    Lancet Oncol; 2014 Jul; 15(8):886-93. PubMed ID: 24954805
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized phase II trial of S-1 plus irinotecan versus S-1 plus paclitaxel as first-line treatment for advanced gastric cancer (OGSG0402).
    Sugimoto N; Fujitani K; Imamura H; Uedo N; Iijima S; Imano M; Shimokawa T; Kurokawa Y; Furukawa H; Goto M
    Anticancer Res; 2014 Feb; 34(2):851-7. PubMed ID: 24511022
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase I study of triplet combination chemotherapy of paclitaxel, cisplatin and S-1 in patients with advanced gastric cancer.
    Kimura Y; Yano H; Imamura H; Fujitani K; Imano M; Tokunaga Y; Matsuoka M; Kurokawa Y; Shimokawa T; Takiuchi H; Tsujinaka T; Furukawa H
    Jpn J Clin Oncol; 2013 Feb; 43(2):125-31. PubMed ID: 23225911
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [The effectiveness of S-1 based sequential chemotherapy as second-line treatment for advanced/recurrent gastric cancer].
    Sugimoto N; Narahara H; Sakai D; Yamamoto S; Fumoto S; Yagi T; Imamura F; Iishi H; Tatsuta M
    Gan To Kagaku Ryoho; 2009 Mar; 36(3):417-24. PubMed ID: 19295265
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Feasibility study of biweekly CPT-11 plus CDDP for S-1- and paclitaxel-refractory, metastatic gastric cancer.
    Yoshida T; Yoshikawa T; Tsuburaya A; Kobayashi O; Hasegawa S; Osaragi T; Sairenji M
    Anticancer Res; 2006; 26(2B):1595-8. PubMed ID: 16619577
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Second-line chemotherapy in gastric cancer following S-1 with CPT-11 chemotherapy performed as clinical trial].
    Inokuchi M; Yamashita T; Yamada H; Kojima K; Sekita Y; Kawano T; Sugihara K
    Gan To Kagaku Ryoho; 2007 Jun; 34(6):875-9. PubMed ID: 17565249
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomized phase II study of second-line chemotherapy with the best available 5-fluorouracil regimen versus weekly administration of paclitaxel in far advanced gastric cancer with severe peritoneal metastases refractory to 5-fluorouracil-containing regimens (JCOG0407).
    Nishina T; Boku N; Gotoh M; Shimada Y; Hamamoto Y; Yasui H; Yamaguchi K; Kawai H; Nakayama N; Amagai K; Mizusawa J; Nakamura K; Shirao K; Ohtsu A;
    Gastric Cancer; 2016 Jul; 19(3):902-10. PubMed ID: 26386560
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Clinical experience of chemotherapy with S-1/CDDP for highly-advanced gastric cancer].
    Uchima Y; Kosaka K; Kimura K; Okita Y; Sim JK; Aomatsu N; Hirata K; Lee WH; Lee T; Nishii T; Tei S; Takeuchi K
    Gan To Kagaku Ryoho; 2010 Jul; 37(7):1287-90. PubMed ID: 20647711
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination chemotherapy of S-1 and low-dose twice-weekly cisplatin for advanced and recurrent gastric cancer in an outpatient setting: a retrospective study.
    Tsuji A; Shima Y; Morita S; Uchida M; Okamoto K; Morita M; Horimi T; Shirasaka T
    Anticancer Res; 2008; 28(2B):1433-8. PubMed ID: 18505092
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Neoadjuvant chemotherapy with combined S-1 plus weekly low-dose cisplatin followed by surgical resection for advanced gastric cancer].
    Isobe T; Hashimoto K; Kizaki J; Miyagi M; Aoyagi K; Koufuji K; Shirouzu K
    Gan To Kagaku Ryoho; 2013 Oct; 40(10):1331-5. PubMed ID: 24105055
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A pilot study of combination chemotherapy with S-1 and low-dose cisplatin for highly advanced gastric cancer.
    Takahashi T; Saikawa Y; Yoshida M; Kitagawa Y; Otani Y; Kubota T; Kumai K; Kitajima M
    Anticancer Res; 2006; 26(2B):1631-5. PubMed ID: 16619584
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Irinotecan plus cisplatin therapy and S-1 plus cisplatin therapy for advanced or recurrent gastric cancer in a single institution.
    Nakashima K; Hironaka S; Boku N; Onozawa Y; Fukutomi A; Yamazaki K; Yasui H; Taku K; Kojima T; Machida N
    Jpn J Clin Oncol; 2008 Dec; 38(12):810-5. PubMed ID: 18988666
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A multicentre randomised trial comparing weekly paclitaxel + S-1 with weekly paclitaxel + 5-fluorouracil for patients with advanced gastric cancer.
    Huang D; Ba Y; Xiong J; Xu N; Yan Z; Zhuang Z; Yu Z; Wan H; Zhang Y; Deng T; Zheng R; Guo Z; Hu C; Wang M; Yu Z; Yao Y; Meng J
    Eur J Cancer; 2013 Sep; 49(14):2995-3002. PubMed ID: 23810466
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase 1/2 clinical study of irinotecan and oral S-1 (IRIS) in patients with advanced gastric cancer.
    Komatsu Y; Yuki S; Fuse N; Kato T; Miyagishima T; Kudo M; Kunieda Y; Tateyama M; Wakahama O; Meguro T; Sakata Y; Asaka M
    Adv Ther; 2010 Jul; 27(7):483-92. PubMed ID: 20559897
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Examination of second-line therapies following administration of low-dose TS-1+CDDP for highly-advanced gastric cancer].
    Kamata T; Furukawa H; Ishii K; Senda K; Yoshimoto K; Tajima H; Takeda T; Kanno M
    Gan To Kagaku Ryoho; 2004 Jul; 31(7):1047-50. PubMed ID: 15272583
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Feasibility and efficacy of combination chemotherapy with S-1 and fractional Cisplatin for advanced gastric cancer.
    Takahashi T; Saikawa Y; Takaishi H; Takeuchi H; Wada N; Oyama T; Nakamura R; Kitagawa Y
    Anticancer Res; 2010 Sep; 30(9):3759-62. PubMed ID: 20944165
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.